A B S T R A C T Immunoreactive parathyroid hormone (PTH) in nonparathyroid malignant tumors associated with hypercalcemia and hypophosphatemia in the absence of demonstrable bone metastases was determined by radioimmunoassay and immunofluorescent techniques. Six of seven tumors contained material with immunological cross-reactivity to bovine PTH by radioimmunoassay and immunofluorescence. The intensity of the immunofluorescent stain varied considerably in the different tumors. From 15 to 90% of neoplastic cells were stained specifically with fluorescein-labeled anti-PTH. In contrast, normal parathyroid glands and parathyroid adenomas showed uniform distribution of immunofluorescence in all parenchymal cells. In one malignant tumor, PTH was localized also by immunoautoradiography. In every case PTH was detected only in the cytoplasm of parenchymal cells. One patient lacked detectable PTH in his tumor, yet showed regression of the hypercalcemia to normal values after removal of large masses of neoplastic tissue and recurrence of hypercalcemia when new growth occurred.
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Dilutional radioimmunoassay curves of nonparathyroid malignant tumors were in most cases different INTRODUCTION Nonparathyroid malignant tumors in patients without skeletal metastasis may be associated with hypercalcemia, hypophosphatemia, and clinical complications indistinguishable from the syndrome of primary hyperparathyroidism (1, 2) . Various immunologic techniques have demonstrated parathyroid hormone (PTH)1 in extracts of kidney, lung, liver, adrenal, parotid, spleen, and breast tumors (3) (4) (5) (6) . A venous-arterial gradient for PTH was found in cases due to hepatoma (5) and hypernephroma (7) . Some malignancies may produce humoral factors other than PTH capable of inducing hypercalcemia, since it is known that bone resorption is stimulated by a variety of biological agents, including 1,25- hydroxycholecalciferol, vitamin A, and prostaglandin El 1Abbreviations used in this paper: HPTH, human parathyroid tissue extract; PBS, phosphate-buffered saline; PTH, parathyroid hormone.
The Journal of Clinical Investigation Volume 53 June 1974-1726-1735 (8) . Gordan , Cantino, Erhardt, Hansen, and Lubich (9) related hypercalcemia to the production of a sterol by some breast carcinomas, while Powell, Singer, Murray, Minkin, and Potts (10) found no radioimmunoassayable PTH in extracts of 11 malignant tumors associated with hypercalcemia and hypophosphatemia, five of which produced bone resorption in vitro.
In malignant tumors secreting PTH, the concentration of the hormone, based on dry weight measurements, is 30-300 times lower than in parathyroid adenomas (4) . The lower concentration of PTH in these nonparathyroid neoplasms may be due to a slower rate of synthesis or more rapid turnover in most of the cells or to high levels of production by only a small fraction of the neoplastic cells.
We present here studies of the content, intracellular localization, and chromatographic characteristics of PTH in normal parathyroid glands, parathyroid adenomas, and nonparathyroid malignant tumors associated with ectopic hyperparathyroidism.
METHODS
Subjects. Ectopic production of PTH was investigated in patients with malignancies accompanied by hypercalcemia with no evidence of bone metastasis by X ray or at autopsy. In those cases in which a careful exploration of the parathyroid glands was performed at autopsy, the parathyroid glands were found to be normal (Table I) . Normal parathyroid glands were obtained at autopsies of patients without a history of metabolic or endocrine diseases. Parathyroid adenomas were obtained during surgical exploration of patients with a diagnosis of primary hyperparathyroidism.
Preparation of tissue extracts. Normal parathyroid glands, parathyroid adenomas, and malignant tumors were obtained during surgery or within 7 h after death. The specimens were placed in liquid nitrogen or dry ice and kept at -200C. Tissue was homogenized in a VirTis 45 homogenator (VirTis Co., Inc., Gardiner, N. Y.) in a volume of 40% acetone in lo acetic acid equal to 10 times the fresh weight of the tissue. The homogenized tissue was centrifuged for 10 min at 27,000 g in a refrigerated centrifuge. The supernate was lyophilized and resuspended in 2-5 ml of acetone-acetic acid solution or in 0.2 M ammonium acetate buffer, pH 4.6 and centrifuged as indicated above. The extract was stored at -20'C. Protein content in tissue extracts was measured by the method of Lowry, Rosebrough, Farr, and Randall (11) .
Radioimmunoassay of PTH. The method of Berson, Yalow, Aurbach, and Potts (12) was used. Samples were incubated for 5 days in 2.5 ml of a 1: 5 dilution of human or sheep hypoparathyroid plasma in 0.02 M Veronal buffer pH 8.6 containing Trasylol (FBA Pharmaceuticals, Inc., New York) 400-500 KIU/ml and 0.5%o of guinea pig serum. Separation of antibody-bound from free hormone was accomplished with 50-mg talcum tablets (13, 14) . Tissue extracts were diluted in hypoparathyroid plasma for radioimmunoassay. "Control" tubes containing the highest concentration of tumor extracts in the absence of antibody were run in every case. Antiserum GP 012-6-23 was used in most tissue studies. This antiserum was obtained in our cells was estimated by direct counting at the microscope by two operators. Since fluorescence fades rather rapidly when exposed to ultraviolet light, each microscopic preparation consisted of three serial sections of tissue mounted on one slide. Enough space was left between the sections in order that only one section was exposed to ultraviolet light at any time. One viewer examined the first section, a second viewer the second section, and a photograph was taken of the third section. These studies were repeated at least five times for each tissue. Controls were used to determine the specificity of immunofluorescent stain as follows: (a) normal guinea pig serum was used instead of PTH antiserum; (b) PTH antiserum was absorbed by incubation with increasing concentrations of human parathyroid extract (0-1 mg protein/ml) for 72 h at 40C. In Immuno-autoradiography was performed as follows: the IgG fraction of anti-PTH guinea pig serum (GP 012-6-23) was obtained with a modification of the method of Goldstein, Slizys, and Chase (15). To 0.5 ml of guinea pig serum anti-PTH diluted in 1.5 ml of PBS, 2 ml of saturated ammonium sulfate solution pH 7.0 was added drop by drop in 30 min at 0C. After centrifugation at 2,000 rpm at 10C for 20 min, the supernate was decanted, and the pellet was resuspended in 2 ml of PBS. Dialysis was carried out at 4°C against PBS for 16 h. The retentate was concentrated to 1 ml using a Centriflo membrane concentrator (Amicon Corp., Lexington, Mass.).
Immunoglobulins were purified in a DEAE-Sephadex A-50 (Pharmacia Fine Chemicals Inc., Piscataway, N. J.), 60 X 1-cm column with PBS, pH 7.2 as eluent. The Sephadex was prepared as indicated by the manufacturer, and the pH was adjusted to 7.2. A single sharp peak at 280 ntm absorbancy was observed at the void volume corresponding to IgG. The fraction (2 ml) showing the highest absorbancy was concentrated to approximately 3 mg of protein/ml using a Centriflo membrane concentrator.
IgG was labeled with 'I by the method of Hunter and
Greenwood (16) Superimposable radioimmunoassay curves were obtained with an extract of a parathyroid adenoma and with the extract of pooled parathyroid tissue (HPTH) (Fig. 1B) . Intracellular localization of PTH of an adjacent section of the adenoma is shown in Plate 1B. As in normal parathyroid gland, the adenoma showed fluorescence evenly distributed in all parenchymal cells indicating that PTH was produced by all adenoma cells.
Figs. 1C-iF show the different dilutional curves obtained with extracts of nonparathyroid tumors which produced PTH. The extract of a liver metastasis of an islet cell carcinoma of the pancreas in patient Ha (Fig.  IC) showed a dilutional curve similar to that of normal HPTH, although the crossings of the curves at higher concentrations of extract suggests heterogeneity of the hormone. This heterogeneity appears more evident observing the dilutional curves of tumors Tu, Ro, Ho, and De (Fig. 1 D-G) . The tumor extract of patient McW demonstrated a slope of approximately the same shape as that obtained with HPTH (Fig. 1H) showed almost total loss of the normal liver structure due to severe autolysis; however, immunofluorescent localization was observed in those tumor cells that were spared. The estimated percentage of positive cells in this tumor (Table I) was only approximate and was obtained using a lower magnification than that of Plate iF.
The study of the renal metastasis of a squamous cell carcinoma of the lung in patient De deserves special consideration. A relatively low concentration of PTH was observed by radioimmunoassay of extracts of the renal metastasis (Fig. 1G) . The immunofluorescence studies clearly showed squamous-type cells with specific fluorescence surrounded by nonfluorescent cells (Plate 1G). In normal tissue surrounding carcinomas, no immunofluorescence was detected with the exception of sections of the kidney of patient De in which a distinct localization of immunofluorescent stain was 3 Autoradiographs of sections of other tumors and parathyroid adenomas did not show so clear a picture as in Plate MDD, due to the variable intensity of background. The occurrence of "damaged" labeled IgG and free 'I was relatively high despite being used soon after iodination and purification. observed in some cells which appeared to be normal components of tubular parenchyma (Plate 1GG). We have been unable to find a similar picture in kidneys from normal subjects. No kidney tissue was examined from patients with primary hyperparathyroidism. Extracts of kidney of De without evidence of malignancy gave a very peculiar dilutional curve in radioimmunoassay (Fig. 1G) . These experiments were repeated three times with very similar results. The possibility that acetone-acetic acid extracts contained hydrolytic enzymes capable of destroying PTH during incubation with higher concentrations of extracts was examined. A test substrate for proteolytic enzymes (Azocoll, 50-100 mesh, Calbiochem, San Diego, Calif.) gave a negative result. When the highest concentration of tissue extracts (150 ig protein/ml) used for radioimmunoassay was incubated for 4-5 days in standard diluent at 4VC in the presence of ['I],PTH, there was no significant "damage" of the labeled hormone.
In patient Mo, four masses of tissue obtained upon surgical removal of thoracic melanoma were frozen immediately in liquid nitrogen. PTH could not be demonstrated by radioimmunoassay of extracts or by immunofluorescence of sections. Nevertheless, hypercalcemia and hypophosphatemia returned to normal postoperatively and recurred with recurrence of tumor 2 mo later.
As shown in Fig. 1 , dilutional curves of extracts of nonparathyroid tumors were obtained with protein concentrations of 3-40 times higher than those needed to obtain an appreciable reduction of bound/free ratio with extracts of a pool of normal glands or parathyroid adenomas (HPTH). Most tumor extracts gave a different dilutional curve when compared with HPTH standard (Fig. 1) . These findings prompted us to study the chromatographic fractionation of tumor extracts and HPTH.
Immunoassayable PTH was detected in a large number of fractions upon gel filtration of HPTH, but most of the PTH activity occurred in a narrow region within fractions 63-72 (Fig. 2) . Minor amounts of PTH activity followed in subsequent fractions. It is highly probable that this activity represents immunoreactive fragments of PTH. Gel filtration fractions of tumor Tu extracts contained immunoassayable PTH almost evenly distributed throughout the elution profile. In contrast, fractions of tumor Ha extracts showed immunoassayable PTH in two reasonably restricted areas. As shown in Fig. 2 , the elution of a labeled marker of highly purified bovine PTH during gel filtration of tumors Tu and Ha was delayed when compared with HPTH, probably due to the larger amount of lyophilized tissue extract from nonparathyroid tumors used to obtain measurable amounts of immunoreactive PTH. The volume of the samples applied to the column was Antiserum GP 012-6-23 was used.
identical. Displacement of the marker was also observed during elution of extracts tumor Tu. Such increased heterogeneity was also observed in dilutional curves of radioimmunoassays of tumor extracts (Fig. 1) . The concentration of PTH in peripheral venous blood was elevated in two of the four patients tested in whom PTH was demonstrated in tumor extracts. Using the same techniques and same antiserum, plasma PTH was elevated in 14 of 17 cases of surgically proved primary hyperparathyroidism.
DISCUSSION
Ectopic hormone production by malignant neoplasms was postulated 40 yr ago by Leyton (17) and later by Albright (18) . It was not until the last decade, with the development of immunologic techniques for the determination of polypeptide hormones, that a more systematic exploration of this field began (19, 20) .
Immunoreactive PTH has been described in extracts of at least a dozen nonparathyroid malignant tumors from patients presenting with a clinical picture resembling primary hyperparathyroidism (3) (4) (5) (6) (7) . In most cases the concentration of PTH in tumors was 30-300 times lower than in parathyroid adenomas (4) (5) (6) (21) and that this heterogeneity according to molecular size is more pronounced in nonparathyroid malignant tumors than in parathyroid extracts. MIarked differences were found among the tumors. Immunologic differences between circulating PTH in primary hyperparathyroidism and in ectopic hormone production by nonparathyroid neoplasms have been reported by Riggs, Arnaud, Reynolds, and Smith (20) .
The presence of immunoreactive PTH in apparently normal kidney tissue in patient De prompted us to more detailed studies (22 (23, 24) . It is not clear whether the PTH found in renal cells is performing a physiological role, undergoing degradation, or simply being stored. Whatever the answer may be, all the information available indicates that exogenous PTH is rapidly localized in the kidney and to a minor degree in other soft tissues, i.e., muscle, liver, and lung. Therefore, it is likely that Plate 1GG illustrates a similar event occurring in a patient with an increased production of endogenous PTH by a nonparathyroid neoplasm.
The clinical picture resembling hyperparathyroidism in patient Mo, who lacked detectable immunoreactive PTH, has strong similarities to those described by Powell et al. (10) . These authors did not detect immunoreactive PTH, using several antisera, in blood and tumor extracts of 11 patients with nonparathyroid malignancies and hypercalcemia. Remission of hypercalcemia occurred in nine patients after antitumor therapy, and extracts of five tumors produced active calcium resorption from bone in vitro. Interest in the possibility that prostaglandins accounted for the calciummobilizing effect is high because of the availability of indomethacin as a potential therapeutic agent (25) . Bioassay of tumor extract was not performed in patient Mo of our series, but this patient showed remission of hypercalcemia after the removal of large tumor masses and its recurrence with renewed tumor growth. It appears, therefore, that the hypercalcemia occurring in malignancies is related, in some cases, to a humoral substance other than PTH. Although this may be the case, we feel that it is rather premature to reject the possibility that fragments of PTH with biological but without detectable immunological activities are the cause of the hypercalcemia, since most antisera have been obtained immunizing with whole bovine PTH.
Earlier studies fronm our laboratory (26) demonstrated the presence of polypeptides in extracts from human urine with biological PTH-like activity but lacking immune cross-reactivity wvith PTH. In patients with primary hyperparathyroidism and with hypercalcemia associated with cancer, higher excretion of those polypeptides was found. Therefore, it is possible that biologically active fragments of PTH are present in primary and ectopic hyperparathyroidism which are undetectable by current antisera. Due to striking heterogeneity of the hormone in the nonparathyroid neoplasms, components may or may not be detected immunologically. On the other hand, in parathyroid adenomas in which heterogeneity is less pronounced, immunoreactive PTH is readily detected in tissue and frequently in blood. In view of these considerations, it is our impression that in nonparathyroid malignant tumors associated with hypercalcemia and lacking immunoreactive PTH, the presence of fragments of PTH with biological activity cannot be ruled out. This problem will not be answered until the minimum structural requirements for biological activity of human PTH are established or other calcium-mobilizing substances are isolated from such tumors and characterized in detail.
These studies clearly demonstrate that certain nonparathyroid tumors contain substantial amounts of immunoreactive PTH in many or most of the neoplastic cells. However not all cells contain detectable immunoreactive PTH at a given time. It is conceivable that the synthesis of PTH occurs intermittently and asynchronously; alternatively, in each of these tumors there may be several cell clones growing simultaneously only one of which had undergone the genetic derepression presumably responsible for the synthesis of PTH.
